These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21905777)

  • 1. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 2. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 3. Future of hepatitis C therapy: development of direct-acting antivirals.
    Dore GJ; Matthews GV; Rockstroh J
    Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hepatitis C in patients infected with human immunodeficiency virus in the direct-acting antiviral era.
    Soriano V; Labarga P; Vispo E; Fernández-Montero JV; Barreiro P
    Infect Dis Clin North Am; 2012 Dec; 26(4):931-48. PubMed ID: 23083825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New pharmacotherapy for hepatitis C.
    Assis DN; Lim JK
    Clin Pharmacol Ther; 2012 Sep; 92(3):294-305. PubMed ID: 22850602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 8. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
    Seden K; Back D; Khoo S
    J Antimicrob Chemother; 2010 Jun; 65(6):1079-85. PubMed ID: 20335191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
    Seden K; Back D
    Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C in 2012.
    Lemon M
    S D Med; 2012 Nov; 65(11):432-3. PubMed ID: 23189411
    [No Abstract]   [Full Text] [Related]  

  • 12. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 13. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
    Soriano V; Sherman KE; Rockstroh J; Dieterich D; Back D; Sulkowski M; Peters M
    AIDS; 2011 Nov; 25(18):2197-208. PubMed ID: 21866039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutics: new drugs hit the target.
    Schlütter J
    Nature; 2011 Jun; 474(7350):S5-7. PubMed ID: 21666733
    [No Abstract]   [Full Text] [Related]  

  • 17. Virology: fresh assault on hepatitis C.
    Rice CM
    Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of human immunodeficiency virus infection in patients infected with the hepatitis C virus.
    Valle Tovo C; Alves de Mattos A; Ribeiro de Souza A; Ferrari de Oliveira Rigo J; Lerias de Almeida PR; Galperim B; Riegel Santos B
    Liver Int; 2007 Feb; 27(1):40-6. PubMed ID: 17241379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.